TWI714092B - 一種抗間皮素抗體及其抗體藥物綴合物 - Google Patents
一種抗間皮素抗體及其抗體藥物綴合物 Download PDFInfo
- Publication number
- TWI714092B TWI714092B TW108117459A TW108117459A TWI714092B TW I714092 B TWI714092 B TW I714092B TW 108117459 A TW108117459 A TW 108117459A TW 108117459 A TW108117459 A TW 108117459A TW I714092 B TWI714092 B TW I714092B
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- seq
- drug conjugate
- heavy chain
- light chain
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims description 93
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims description 93
- 229940127121 immunoconjugate Drugs 0.000 title abstract 2
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims abstract description 52
- 102100025096 Mesothelin Human genes 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 42
- 239000012634 fragment Substances 0.000 claims abstract description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims description 37
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 31
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims description 14
- 102000003735 Mesothelin Human genes 0.000 claims description 14
- 108090000015 Mesothelin Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 23
- 238000000034 method Methods 0.000 abstract description 15
- 230000008685 targeting Effects 0.000 abstract description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 31
- 108010093470 monomethyl auristatin E Proteins 0.000 description 29
- 229930012538 Paclitaxel Natural products 0.000 description 21
- 229960001592 paclitaxel Drugs 0.000 description 21
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000562 conjugate Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- AMKBTTRWLGVRER-OFVILXPXSA-N n-[(2s)-1-[[(2s)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(CO)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O AMKBTTRWLGVRER-OFVILXPXSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- NLMBVBUNULOTNS-HOKPPMCLSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o Chemical compound C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN3C(C=CC3=O)=O)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 NLMBVBUNULOTNS-HOKPPMCLSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 4
- 229930188854 dolastatin Natural products 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- -1 1,3,5-tripropenylhexahydro-1,3,5-triazine-thioglycolic acid Chemical compound 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 0 CC[C@@](C(C)C)*=C[*@](*)[C@@](CCCCC(*)*1CC1)C(*c1ccc(C*C(CC)=O)cc1)=N Chemical compound CC[C@@](C(C)C)*=C[*@](*)[C@@](CCCCC(*)*1CC1)C(*c1ccc(C*C(CC)=O)cc1)=N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- FPDWHGAQJGAILQ-UHFFFAOYSA-N C(O)(O)=O.[N+](=O)([O-])C1=CC=CC=C1.[N+](=O)([O-])C1=CC=CC=C1 Chemical compound C(O)(O)=O.[N+](=O)([O-])C1=CC=CC=C1.[N+](=O)([O-])C1=CC=CC=C1 FPDWHGAQJGAILQ-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000272194 Ciconiiformes Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960005558 mertansine Drugs 0.000 description 2
- 108010059074 monomethylauristatin F Proteins 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000002456 taxol group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VEGGTWZUZGZKHY-GJZGRUSLSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)-n-[4-(hydroxymethyl)phenyl]pentanamide Chemical compound NC(=O)NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)NC1=CC=C(CO)C=C1 VEGGTWZUZGZKHY-GJZGRUSLSA-N 0.000 description 1
- SGRJLTOOQLQDRH-UHFFFAOYSA-N 2-[[2,4-dicarboxybutyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CC(C(O)=O)CCC(O)=O SGRJLTOOQLQDRH-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000237967 Aplysia Species 0.000 description 1
- 241000237373 Aplysia sp. Species 0.000 description 1
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 239000012626 DNA minor groove binder Substances 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 1
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229940119336 Microtubule stabilizer Drugs 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 1
- 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000283925 Spermophilus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000007185 Stork enamine alkylation reaction Methods 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 101150094313 XPO1 gene Proteins 0.000 description 1
- PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
- LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 description 1
- WZEAGSMYTVSXQA-XZZQEHRXSA-N [4-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methox Chemical compound C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](N)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 WZEAGSMYTVSXQA-XZZQEHRXSA-N 0.000 description 1
- HYSPJPGXSALJRR-DHIFEGFHSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(COC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O HYSPJPGXSALJRR-DHIFEGFHSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- XNEYCQMMVLAXTN-UHFFFAOYSA-N carbonic acid;magnesium Chemical compound [Mg].OC(O)=O XNEYCQMMVLAXTN-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 108010045552 dolastatin 15 Proteins 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 102000055862 human MUC16 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- DASWEROEPLKSEI-UIJRFTGLSA-N monomethyl auristatin e Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本發明公開了一種靶向於MSLN的抗體藥物綴合物。本發明還公開了製備所述抗體藥物綴合物(ADC)的方法。本發明還公開了一種新型的MSLN抗體或其功能性片段,其包含經改造的重鏈和輕鏈。
Description
本發明涉及一種抗間皮素抗體或其功能性片段。本發明還涉及包含抗間皮素抗體和小分子藥物的抗體藥物綴合物。本發明還涉及本發明的抗體和綴合物在製備用於治療腫瘤的藥物中的用途。
MSLN(間皮素、Mesothelin)是由單克隆抗體CAK1在間皮細胞、間皮瘤和卵巢癌中識別的抗原,是一種分子為40kDa的細胞表面糖蛋白,其高表達於多種腫瘤組織中,為一個非常好的治療型抗體的靶向標誌物。
雖然單克隆抗體治療靶點特異性高,副作用低,但是單獨使用時療效比較有限。抗體藥物綴合物是將毒素通過連接子與抗體相連,其同時具有較強的靶向性和高效的細胞毒性兩大特點,使得ADC新藥成為最有前景的免疫治療方法之一,在癌症免疫治療中備受關注。
已有一些研究小組構建了靶向MSLN的抗體藥物綴合物,但是這些抗體藥物綴合物仍然存在著諸多缺點,例如:通過抗體上半胱氨酸的巰基進行偶聯會導致抗體的肽鏈之間原本的二硫鍵喪失,得到的ADC不穩定,一旦進入迴圈,ADC的半衰期會縮短,毒副作用較大;利用抗體上賴氨酸的氨基進行偶聯使得偶聯位點隨機,影響抗體的靶向性。
因此,本領域中仍然需要開發具有更加優越性質的MSLN抗體以及包含該抗體的抗體藥物綴合物。
本發明提供了一種抗間皮素抗體或其功能性片段,以及包含該抗體或其功能性片段的抗體藥物綴合物。特別地,本發明的抗體藥物綴合物具有更高的穩定性和更低的毒副作用,和/或對間皮素具有更高的親和力。
具體的:一方面,本發明提供了一種抗體藥物綴合物,其中所述抗體藥物綴合物的結構通式為:Ab-(L-D)n
其中:所述Ab為特異性結合MSLN的抗體或其功能性片段;所述L為空或任一連接子;所述D為任一治療劑;n為選自1到8的整數,例如1、2、3、4、5、6、7或8或其任意兩者的區間。
進一步的,本發明的抗體或其功能性片段包含重鏈和輕鏈,其中(i)所述重鏈包含至少三個CDR區,其中所述CDR區中至少一個的氨基酸序列具有如SEQ ID NO:1、2或3所示的氨基酸序列或者與其具有至少80%(優選85%、90%、95%、98%或者99%)序列同一性的序列;並且(ii)所述輕鏈包含至少三個CDR區,其中所述CDR區中至少一個的氨基酸序列具有如SEQ ID NO:4、5或6所示的氨基酸序列或者與其具有至少80%(優選85%、90%、95%、98%或者99%)序列同一性的序列。優選的,本發明的 抗體或其功能性片段包含重鏈和輕鏈,其中(i)所述重鏈可變區包含三個CDR區,其中所述CDR區分別具有如SEQ ID NO:1、2或3所示的氨基酸序列;和/或(ii)所述輕鏈可變區包含三個CDR區,其中所述CDR區分別具有如SEQ ID NO:4、5或6所示的氨基酸序列。最優選的,本發明公開的抗間皮素抗體重鏈的CDR的氨基酸序列分別如SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3所示,其輕鏈可變區的CDR的氨基酸序列分別如SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6所示。
更進一步的,本發明提供了一種抗間皮素抗體或其功能性片段,其包括重鏈可變區和輕鏈可變區,其中(i)所述重鏈可變區包含SEQ ID NO:7所示的氨基酸序列或者與其具有至少80%(優選85%、90%、95%、98%或者99%)序列同一性的序列;並且(ii)所述輕鏈可變區包含SEQ ID NO:8所示的氨基酸序列或者與其具有至少80%(優選85%、90%、95%、98%或者99%)序列同一性的序列。優選的,所述抗體包含重鏈和輕鏈,其中(i)所述重鏈可變區包含SEQ ID NO:7所示的氨基酸序列,和/或(ii)所述輕鏈可變區包含SEQ ID NO:8所示的氨基酸序列。最優選的本發明公開的抗間皮素抗體重鏈可變區包含SEQ ID NO:7所示的氨基酸序列,所述輕鏈可變區包含SEQ ID NO:8所示的氨基酸序列。
在某些具體實施方案中,本發明的抗體包含重鏈和輕鏈,其中所述重鏈包含SEQ ID NO:10所示的氨基酸序列,所述輕鏈包含SEQ ID NO:9所示的氨基酸序列。
另一方面,本發明提供了抗體藥物綴合物,其包含抗間皮素抗體或其功能性片段以及治療劑。優選地,本發明的抗體藥物綴合物還包含連 接子,其將所述抗間皮素抗體或其功能性片段與治療劑相連。
在某些實施方案中,本發明的連接子L可通過本領域已知的任何方式與抗體連接,優選地通過巰基和/或氨基連接。在一個優選的方案中,本發明的抗體通過抗體上的巰基與連接子連接。本發明中的連接子L可以不存在(即抗體與治療劑D直接相連)或者任一可裂解(即可在體內環境下發生斷裂的接頭)或者不可裂解的連接子或者其組合,優選的,所述連接子可以選自下表1中所列出的那些。
在一些實施方案中,本發明的連接子優選的選自下表2中所列出的那些連接子。
在本發明的一些實施方案中,所述治療劑D選自:美坦生類化合物、V-ATP酶抑制劑、促凋亡劑、Be 12抑制劑、McL1抑制劑、HSP90抑制劑、IAP抑制劑、mTOr抑制劑、微管穩定劑、微管去穩定劑、阿裡他汀(auristatin)、朵拉司他汀(dolastatin)、MetAP(甲硫氨酸氨肽酶)、蛋白質CRMl的核輸出抑制劑、DPPIV抑制劑、蛋白酶體抑制劑、線粒體中磷醯基轉移反應的抑制劑、蛋白質合成抑制劑、激酶抑制劑、CDK2抑制劑、CDK9抑制劑、驅動蛋白抑制劑、HDAC抑制劑、DNA損傷劑、DNA烷基化劑、DNA嵌入劑、DNA小溝結合劑、DHFR抑制劑、以及海兔毒素肽。
在本發明的一些優選實施方案中,所述治療劑D為細胞毒類物質(例如抗代謝藥、抗腫瘤抗生素、生物鹼)、免疫增強劑或放射性同位素。優選地,所述治療劑D可選自MMAD(單甲基澳瑞他汀D,Monomethyl auristatin D)及其衍生物、MMAE(單甲基澳瑞他汀E,Monomethyl auristatin E)及其衍生物、MMAF(單甲基澳瑞他汀F,Monomethyl auristatin F)及其衍生物、美登素類衍生物DM1(Mertansine derivative M1)、美登素類衍生物DM4(Mertansine derivative M4)、Duocarmycine、Calicheamicin、PBDA(Pyrrolobenzodiazepines)、Doxorubicin、Vinca Alkaloids、Metrotrexate、Vinblastine、Daunorubicin,更優選地所述治療劑選自美登素類(maytansinoids)(例如安絲菌素(Ansamitocin)或者美登素(Mertansine))、海兔毒素肽(dolastatin)及其衍生物,最優選地所述治療劑選自MMAD和MMAE。
在某些具體實施方案中,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,Ab為本發明所述的任一抗間皮素抗體,L選自 Py-MAA-Val-Cit-PAB、Mc-Val-Cit-PAB,D選自MMAD或MMAE,以及n為選自1到8的整數,例如1、2、3、4、5、6、7、8或其任意兩者的區間。
特別地,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,其中Ab為本發明所述的任一抗間皮素抗體,所述抗體的重鏈可變區的CDR氨基酸序列分別如SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3所示,所述抗體的輕鏈可變區的CDR氨基酸序列分別如SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6所示;L為Py-MAA-Val-Cit-PAB,D為MMAE。更特別地,本發明的抗體藥物綴合物為RC88-Py-MAA-Val-Cit-PAB-MMAE,其具有下式所示的結構,其中n為1、2、3、4、5、6、7或8:
RC88-Py-MAA-Val-Cit-PAB-MMAE
特別地,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,其中Ab為本發明所述的任一抗間皮素抗體,所述抗體的重鏈可變區的CDR的氨基酸序列分別如SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3所示,所述抗體的輕鏈可變區的CDR的氨基酸序列分別如SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6所示;L為Py-MAA-Val-Cit-PAB,D為MMAD。更特別地,本發明的抗體藥物綴合物為RC88-Py-MAA-Val-Cit-PAB-MMAD,其具有下式所示的結構,其中n為1、2、3、4、5、6、7或8:
RC88-Py-MAA-Val-Cit-PAB-MMAD
特別地,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,其中Ab為本發明所述的任一抗間皮素抗體,所述抗體的重鏈可變區的CDR的氨基酸序列分別如SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3所示,所述抗體的輕鏈可變區的CDR的氨基酸序列分別如SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6所示;L為Mc-Val-Cit-PAB,D為MMAE。更特別地,本發明的抗體藥物綴合物為RC88-Mc-Val-Cit-PAB-MMAE,其具有下式所示的結構,其中n為1、2、3、4、5、6、7或8:
RC88-Mc-Val-Cit-PAB-MMAE
特別地,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,其中Ab為本發明所述的任一抗間皮素抗體,所述抗體的重鏈可變區的CDR的氨基酸序列分別如SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3所示,所述抗體的輕鏈可變區的CDR的氨基酸序列分別如SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6所示;L為Mc-Val-Cit-PAB,D為MMAD。更特別地,本發明的抗體藥物綴合物為RC88-Mc-Val-Cit-PAB-MMAD,其具有下式所示的結構,其中n為1、2、3、4、5、6、7或8:
RC88-Mc-Val-Cit-PAB-MMAD
特別地,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,其中Ab為本發明所述的任一抗間皮素抗體,所述抗體具有SEQ ID NO:7所示的重鏈可變區序列和SEQ ID NO:8所示的輕鏈可變區序列;L為Py-MAA-Val-Cit-PAB,D為MMAE。更特別地,本發明的抗體藥物綴合物為RC88-Py-MAA-Val-Cit-PAB-MMAE,其具有下式所示的結構,其中n為1、2、3、4、5、6、7或8:
RC88-Py-MAA-Val-Cit-PAB-MMAE
特別地,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,其中Ab為本發明所述的任一抗間皮素抗體,所述抗體具有SEQ ID NO:7所示的重鏈可變區序列和SEQ ID NO:8所示的輕鏈可變區序列;L為Py-MAA-Val-Cit-PAB,D為MMAD。更特別地,本發明的抗體藥物綴合物 為RC88-Py-MAA-Val-Cit-PAB-MMAD,其具有下式所示的結構,其中n為1、2、3、4、5、6、7或8:
RC88-Py-MAA-Val-Cit-PAB-MMAD
特別地,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,其中Ab為本發明所述的任一抗間皮素抗體,所述抗體具有SEQ ID NO:7所示的重鏈可變區序列和SEQ ID NO:8所示的輕鏈可變區序列;L為Mc-Val-Cit-PAB,D為MMAE。更特別地,本發明的抗體藥物綴合物為RC88-Mc-Val-Cit-PAB-MMAE,其具有下式所示的結構,其中n為1、2、3、4、5、6、7或8:
RC88-Mc-Val-Cit-PAB-MMAE
特別地,本發明涉及結構通式為Ab-(L-D)n的抗體藥物綴合物,其中Ab為本發明所述的任一抗間皮素抗體,所述抗體的具有SEQ ID NO:7所示的重鏈可變區序列和SEQ ID NO:8所示的輕鏈可變區序列;L為Mc-Val-Cit-PAB,D為MMAD。更特別地,本發明的抗體藥物綴合物為RC88-Mc-Val-Cit-PAB-MMAD,其具有下式所示的結構,其中n為1、2、3、 4、5、6、7或8:
RC88-Mc-Val-Cit-PAB-MMAD
另一方面,本發明提供了一種能夠結合間皮素的抗體或其功能性片段,所述的抗體或其功能性片段包含重鏈和輕鏈,其中(i)所述重鏈包含至少三個CDR區,其中所述CDR區中至少一個的氨基酸序列具有如SEQ ID NO:1、2或3所示的氨基酸序列或者與其具有至少80%(優選85%、90%、95%、98%或者99%)序列同一性的序列;和/或(ii)所述輕鏈包含至少三個CDR區,其中所述CDR區中至少一個的氨基酸序列具有如SEQ ID NO:4、5或6所示的氨基酸序列或者與其具有至少80%(優選85%、90%、95%、98%或者99%)序列同一性的序列。
在某些具體的實施方案中,本發明的抗間皮素抗體或其功能性片段包含重鏈和輕鏈,其中:(i)所述重鏈可變區包含三個CDR區,其中所述CDR區分別具有如SEQ ID NO:1、2或3所示的氨基酸序列;和/或(ii)所述輕鏈可變區包含三個CDR區,其中所述CDR區分別具有如SEQ ID NO:4、5或6所示的氨基酸序列。
特別地,本發明公開的抗間皮素抗體重鏈的CDR區的氨基酸序列 分別如SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3所示。
特別地,本發明公開的抗間皮素抗體輕鏈的CDR區的氨基酸序列分別如SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6所示。
更特別地,本發明公開的抗間皮素抗體重鏈的CDR區的氨基酸序列分別如SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3所示,其輕鏈可變區的CDR區的氨基酸序列分別如SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6所示。
又一方面,本發明提供了一種抗間皮素抗體或其功能性片段,其包含重鏈和輕鏈,其中所述重鏈和輕鏈分別包含重鏈可變區和輕鏈可變區:(i)所述重鏈可變區包含SEQ ID NO:7所示的氨基酸序列或者與其具有至少80%(優選85%、90%、95%、98%或者99%)序列同一性的序列;並且(ii)所述輕鏈可變區包含SEQ ID NO:8所示的氨基酸序列或者與其具有至少80%(優選85%、90%、95%、98%或者99%)序列同一性的序列。
在某些具體的實施方案中,所述抗體包含重鏈和輕鏈,其中所述重鏈和輕鏈分別包含重鏈可變區和輕鏈可變區,其中(i)所述重鏈可變區包含SEQ ID NO:7所示的氨基酸序列,和/或(ii)所述輕鏈可變區包含SEQ ID NO:8所示的氨基酸序列。
特別地,本發明的抗間皮素抗體包含重鏈和輕鏈,其中所述重鏈 和輕鏈分別包含SEQ ID NO:10和SEQ ID NO:9所示的氨基酸序列。
在某些具體的實施方案中,所述抗間皮素抗體或其功能性片段是分離的。
在某些具體的實施方案中,所述抗間皮素抗體或其功能性片段是單克隆抗體、嵌合抗體、人源化抗體、人抗體、單鏈抗體(scFv)或者雙特異性抗體,在某些具體的實施方案中,所述抗間皮素抗體或其功能性片段是單克隆抗體;在某些具體的實施方案中,所述抗間皮素抗體或其功能性片段是人源化抗體;在某些具體的實施方案中,所述抗間皮素抗體或其功能性片段是IgG1κ抗體。
又一方面,本發明提供了一種編碼本發明涉及抗體的分離的多核苷酸。
又一方面,本發明提供了分離的多核苷酸的組合,所述組合包括編碼本發明抗體或其功能性片段之輕鏈的多核苷酸和編碼本發明抗體或其功能性片段之重鏈的多核苷酸。
又一方面,本發明提供了表達載體或者表達載體的組合,其包含根據本發明的多核苷酸或者根據本發明的多核苷酸的組合,所述多核苷酸與允許其所編碼的多肽在宿主細胞或無細胞表達系統中表達的調節序列有效連接。
又一方面,本發明提供了藥物組合物,其包含根據本發明的抗體或其功能性片段和/或根據本發明的綴合物,以及可藥用載體。
又一方面,本發明提供了一種治療或預防癌症的方法,其包括向有此需要的物件施用治療有效量的根據本發明的抗體、多核苷酸、多核苷酸組合、表達載體、綴合物和/或藥物組合物。
又一方面,本發明提供了根據本發明的抗體、多核苷酸、多核苷酸組合、表達載體、綴合物和/或藥物組合物在製備用於治療或預防癌症的藥物中的用途。
又一方面,本發明提供了根據本發明的抗體、多核苷酸、多核苷酸組合、表達載體、綴合物和/或藥物組合物,其用於治療或預防癌症。
又一方面,本發明提供了任何上述實施方案中的抗體藥物綴合物在製備治療癌症藥物中的用途。
在某些具體的實施方案中,本發明所述的癌症為間皮素陽性癌症。
圖1顯示了RC88-PY-MAA-Val-Cit-PAB-MMAE和RC88-Mc-Val-Cit-PAB-MMAE的SDS-PAGE表徵圖,該圖對RC88抗體與連接子和藥物綴合物的偶聯情況進行了表徵。
圖2顯示了本發明綴合物的偶聯情況,其中圖2A顯示了利用疏水高效液相色譜(HIC-HPLC)法對RC88-PY-MAA-Val-Cit-PAB-MMAE的偶聯情況的檢測結果;圖2B顯示了利用疏水高效液相色譜(HIC-HPLC)法對RC88-Mc-Val-Cit-PAB-mMAE的偶聯情況的檢測結果。
圖3顯示了本發明綴合物的細胞毒作用,其中圖3A顯示了本發明的RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Py-MAA-Val-Cit-PAB-MMAD、RC88-Mc-Val-Cit-PAB-MMAE、
RC88-Mc-Val-Cit-PAB-MMAD)在MSLN高表達的Oval-Citar-3細胞中的細胞毒作用曲線;圖3B顯示了未偶聯抗體的連接子和細胞毒素偶聯物(Py-Val-Cit-PAB-MMAE、Py-Val-Cit-PAB-MMAD、Mc-Val-Cit-PAB-MMAE、Mc-Val-Cit-PAB-MMAD)在MSLN高表達的Oval-Citar-3細胞中的細胞毒作用曲線;C圖顯示了單獨的細胞毒素MMAE、MMAD和陽性對照PTX(Paclitaxel,紫杉醇)在MSLN高表達的Oval-Citar-3細胞中的細胞毒作用曲線。其中橫坐標代表了藥物的對數濃度,縱坐標代表了在對應藥物對數濃度下的最大抑制率。
圖4顯示了施用RC88抗體(2mg/kg)、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAD、RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAD,2mg/kg)及MMAE(0.0716mg/kg)的(每週給藥1次,共給藥3次)荷瘤鼠的體重隨天數變化的曲線圖,其中橫坐標代表了天數,縱坐標代表了荷瘤鼠在實施藥物對應天數下的體重。本試驗中,對照組為生理鹽水(control)和MMAE。
圖5顯示了施用RC88抗體(2mg/kg)、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAD、RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAD,2mg/kg)及MMAE(0.0716mg/kg)的(每週給藥1次,共給藥3次)荷瘤鼠腫瘤體積隨天數變化的曲線圖,其中橫坐標代表了天數,縱坐標代表了荷瘤鼠的腫瘤在實施藥物對應天數下的體積。本試驗中,對照組為生理鹽水(control)和MMAE。
圖6顯示了施用RC88抗體(2mg/kg)、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAD、RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAD,2mg/kg)及MMAE(0.0716mg/kg),每週給藥1次,共給藥3次後荷瘤鼠腫瘤的重量,對照組為生理鹽水(control)和MMAE。
圖7顯示了施用RC88抗體(3mg/kg)、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE 3mg/kg、1.5mg/kg、0.75mg/kg)、MMAE(0.06mg/kg)、RC88抗體(3mg/kg)+MMAE(0.06mg/kg)、IgG-MMAE 3mg/kg、PTX(紫杉醇,10mg/kg)(每週給藥1次,共給藥3次(PTX每週給藥2次,共給藥6次))的荷瘤鼠的體重隨天數變化的曲線圖,其中橫坐標代表了天數,縱坐標代表了荷瘤鼠在實施藥物對應天數下的體重。本試驗中,對照組為生理鹽水(control)和MMAE。
圖8顯示了施用RC88抗體(3mg/kg)、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE 3mg/kg、1.5mg/kg、0.75mg/kg)、MMAE(0.06mg/kg)、RC88抗體(3mg/kg)+MMAE(0.06mg/kg)、IgG-MMAE 3mg/kg、PTX(紫杉醇,10mg/kg)(每週給藥1次,共給藥3次(PTX每週給藥2次,共給藥6次))的荷瘤鼠的腫瘤體積隨天數變化的曲線圖,其中橫坐標代表了天數,縱坐標代表了荷瘤鼠的腫瘤在實施藥物對應天數下的體積。本試驗中,對照組為生理鹽水(control)和MMAE。
圖9顯示了RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE)對MSLN高表達的Oval-Citar-3人卵巢癌荷瘤鼠模型的抑瘤作用。
圖10顯示了通過ELISA實驗測定RC88抗體及RC88抗體藥物綴合物(RC88-Py-MA-Val-Cit-PAB-MMAE)與MSLN陽性腫瘤細胞的親和力曲線。
圖11顯示了本發明綴合物與靶標的親和力,其中圖11A顯示了通過酶標法測定RC88抗體及RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE)與MSLN陽性腫瘤細胞的親和力曲線;圖11B顯示了RC88抗體及RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE)與重組人MSLN蛋白競爭結合曲線。
圖12顯示了RC88抗體及RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE)和CA125與重組人MSLN蛋白的競爭結合曲線。
如除非另有定義,本文使用的所有科技術語具有本領域普通技術人員所理解的相同含義。關於本領域的定義及術語,專業人員具體可參考Current Protocols in Molecular Biology(Ausubel)。氨基酸殘基的縮寫是本領域中所用的指代20個常用L-氨基酸之一的標準3字母和/或1字母代碼。
儘管本發明的廣義範圍所示的數字範圍和參數近似值,但是具體實施例中所示的數值盡可能準確的進行記載。然而,任何數值本來就必然含有一定的誤差,其是由它們各自的測量中存在的標準差所致。另外,本文公開的所有範圍應理解為涵蓋其中包含的任何和所有子範圍。例如記載的“1至10”的範圍應認為包含最小值1和最大值10之間(包含端點)的任何和所有子範圍;也就是說,所有以最小值1或更大起始的子範圍,例如1至6.1,以及以最大值10或更小終止的子範圍,例如5.5至10。另外,任何稱為“併入本文”的參考文獻應理解為以其整體併入。
另外應注意,如本說明書中所使用的,單數形式包括其所指物件的複數形式,除非清楚且明確的限於一個所指物件。術語“或”可與術語“和/或”互換使用,除非上下文另有清楚指明。
本文使用的術語“間皮素”,也稱Mesothelin、MSLN,指源自細胞中間皮素前體蛋白加工的任何天然、成熟間皮素。該術語包括來自任何脊椎動物來源的間皮素,包括哺乳動物諸如靈長類動物(例如人和猿猴)和齧齒類動物(例如小鼠和大鼠),除非另有說明,該術語還包括間皮素的天然存在變體,例如剪接變體或等位變體。
本文使用的術語“藥物組合物”、“組合藥物”和“藥物組合”可互換地使用,其表示組合在一起以實現某種特定目的的至少一種藥物以及任選地可藥用載體或輔料的組合。在某些實施方案中,所述藥物組合物包括在時間和/或空間上分開的組合,只要其能夠共同作用以實現本發明的目的。例如,所述藥物組合物中所含的成分(例如根據本發明的抗體、核酸分子、核酸分子組合和/或綴合物)可以以整體施用於物件,或者分開施用於物件。當所述藥物組合物中所含的成分分開地施用于物件時,所述成分可以同時或依次施用於物件。優選地,所述可藥用載體是水、緩衝水溶液、等滲鹽溶液如PBS(磷酸鹽緩衝液)、葡萄糖、甘露醇、右旋葡萄糖、乳糖、澱粉、硬脂酸鎂、纖維素、碳酸鎂、0.3%甘油、透明質酸、乙醇或聚亞烷基二醇如聚丙二醇、甘油三酯等。所用可藥用載體的類型尤其依賴于根據本發明的組合物是否配製為用於口服、鼻、皮內、皮下、肌內或靜脈施用。根據本發明的組合物可包含潤濕劑、乳化劑或緩衝液物質作為添加劑。
根據本發明的藥物組合物、疫苗或者藥物製劑可通過任何適宜的途徑施用,例如可口服、鼻、皮內、皮下、肌內或靜脈內施用。
本文使用的術語“治療劑”表示能夠起到治療作用(例如治療、預防、緩解或抑制任何疾病和/或病症)的任何物質或實體(entity),其包括但不限於:化學治療劑、放射治療劑、免疫治療劑、熱治療劑(thermally therapeutic agent)等。
本文使用的“CDR區”或“CDR”是指免疫球蛋白的重鏈和輕鏈的高變區,如Kabat et al.所定義(Kabat et al.,Sequences of proteins of immunological interest,5th Ed.,U.S.Department of Health and Human Services,NIH,1991,以及以後版本)。存在三個重鏈CDR和三個輕鏈CDR。根據情況,本文所用術語CDR或CDRs是為了指示這些區域之一、或者這些區域的幾個或者甚至 全部,所述區域包含通過抗體對抗原或其識別表位的親和力而負責結合的大部分氨基酸殘基。
對本發明來說,兩種核酸或者氨基酸序列間的“一致性”、“同一性”或“相似性”是指,在最佳比對(最優比對)後所獲得的、待比較的兩序列之間相同核苷酸或相同氨基酸殘基的百分數,該百分數是純粹統計學的並且兩種序列間的差異隨機分佈並覆蓋其全長。兩種核酸或者氨基酸序列之間的序列比較通常是在以最優方式使它們匹配以後,通過比較這些序列而進行,所述比較能夠通過區段或者通過“比較窗”實施。除了能夠手工實施外,用於比較序列的最優比對,還能夠通過Smith和Waterman(1981)[Ad.App.Math.2:482]的局部同源性演算法、通過Neddleman和Wunsch的(1970)[J.MoI.Biol.48:443]局部同源性演算法、通過Pearson和Lipman的(1988)[Proc.Natl.Acad.Sci.USA 85:2444)相似性搜索方法、通過使用這些演算法的電腦軟體實施(GAP、BESTFIT、FASTA和TFASTA in the Wisconsin Genetics Software Package,Genetics Computer Group,575Science Dr.,Madison,WI,或者通過BLAST N or BLAST P比較軟體)。
本文使用的“治療有效量”或“有效量”是指足以顯示其對於所施用物件益處的劑量。施用的實際量,以及施用的速率和時間過程會取決於所治療者的自身情況和嚴重程度。治療的處方(例如對劑量的決定等)最終是全科醫生及其它醫生的責任並依賴其做決定,通常考慮所治療的疾病、患者個體的情況、遞送部位、施用方法以及對於醫生來說已知的其它因素。
本文所使用的術語“物件”是指哺乳動物,如人類,但也可以是其它動物,如野生動物(如蒼鷺、鸛、鶴等),家畜(如鴨、鵝等)或實驗動物(如猩猩、猴子、大鼠、小鼠、兔子、豚鼠、土撥鼠、地松鼠等)。
本文所使用的“抗體”以最廣義使用,並且涵蓋各種抗體結構,包括但不限於單克隆抗體、多克隆抗體、多特異性抗體(例如雙特異性抗體)、和抗體片段,特別的,本文所使用的“抗體”指包含通過二硫鍵而互連的至少兩條重(H)鏈和兩條輕(L)鏈的蛋白。每條重鏈包含一重鏈可變區(縮寫為VH)和一重鏈恒定區。該重鏈恒定區包含三個域(domain),CH1、CH2和CH3。每條輕鏈包含一輕鏈可變區(縮寫為VL)和一輕鏈恒定區。該輕鏈恒定區包含一個域,CL。VH和VL區域還可再細分為具有高可變性的多個區,被稱為互補決定區(CDR),其間散 佈有更為保守的被稱為框架區(FR)的多個區域。每個VH和VL均由三個CDR和四個FR構成,按照以下順序從氨基端至羧基端排布:FR1、CDR1、FR2、CDR2、FR3、CDR3、FR4。重鏈和輕鏈的這些可變區包含與抗原相互作用的結合域。抗體的恒定區可介導免疫球蛋白與宿主的組織或因數結合,包括免疫系統的各種細胞(如效應細胞)和經典補體系統的第一成分(Clq)。嵌合或人源化抗體也涵蓋在根據本發明的抗體中。
術語“人源化抗體”是指一種抗體,其包含來源於非人源抗體的CDR區、並且該抗體分子的其他部分來源於一種(或幾種)人抗體。而且,為了保留結合親和力,可以修飾骨架(稱為FR)區段的一些殘基(Jones et al.,Nature,321:522-525,1986;Verhoeyen et al.,Science,239:1534-1536,1988;Riechmann et al.,Nature,332:323-327,1988)。通過本領域技術人員已知的技術可以製備根據本發明的人源化抗體或其片段(例如,描述於檔Singer et al.,J.Immun.150:2844-2857,1992;Mountain et al.,Biotechnol.Genet.Eng.Rev.,10:1-142,1992;或Bebbington et al.,Bio/Technology,10:169-175,1992)。
術語“嵌合抗體”系指以下抗體,其中的可變區序列來自一物種而恒定區序列來自另一物種,例如可變區序列來自小鼠抗體而恒定區序列來自人抗體的抗體。通過使用基因重組技術可以製備根據本發明的嵌合抗體或其片段。例如,所述嵌合抗體可以通過克隆重組DNA來生產,所述重組DNA包含啟動子和編碼根據本發明的非人尤其是鼠單克隆抗體可變區的序列、以及編碼人抗體恒定區的序列。由這種重組基因編碼的本發明嵌合抗體將是,例如,鼠-人嵌合體,該抗體的特異性由來源於鼠DNA的可變區確定,並且其同種型由來源於人DNA的恒定區來確定。對於製備嵌合抗體的方法,例如,可以參考檔Verhoeyn et al.(BioEssays,8:74,1988)。
術語“單克隆抗體”系指具有單一分子組成的抗體分子的製備物。單克隆抗體組合物顯示出對於特定表位元的單一結合特異性和親和性。
本文所使用的術語“功能性片段”是指抗體片段由其來源抗體的重或輕可變鏈的部分序列構成或者包含它們,所述部分序列足以保留與其來源抗體相同的結合特異性和充分的親和力,優選至少等於其來源抗體親和力的1/100,在更優選方式中至少等於1/10。這種功能片段 將包含最少5個氨基酸,優選其來源的抗體序列的10、15、25、50和100個連續氨基酸。
本文所使用的術語“DAR”是指在抗體藥物綴合物中的藥物-抗體比(Drug-Antibody Ratio),其表示與一個抗體相綴合的藥物的平均數量。優選地,本發明的抗體藥物綴合物具有約2至約6的DAR值,例如約2、2.5、3、3.5、3.6、3.7、3.8、3.9、4、4.1、4.2、4.3、4.4、4.5、5、5.5、6或其任意兩者的區間。
通常,為了製備單克隆抗體或其功能片段,尤其是鼠源的單克隆抗體或其功能片段,可以參考尤其描述在手冊“Antibodies”中的技術(Harlow and Lane,Antibodies:A Laboratory Manual,Cold Spring Harbor Laboratory,Cold Spring Harbor NY,pp.726,1988)或者參考Kohler和Milstein描述的從雜交瘤細胞製備的技術(Nature,256:495-497,1975)。
根據本發明的單克隆抗體或者抗體藥物綴合物可以是純化的,例如可以在親和柱上純化,已經預先在所述親和柱上固定了MSLN抗原或其包含可被根據本發明所述抗體特異性識別的表位的片段之一。更具體而言,所述單克隆抗體可以如此純化,通過蛋白質A和/或G色譜,接或不接目的在於消除殘留蛋白質污染物以及DNA和LPS的離子交換色譜,其本身接或不接在Sepharose凝膠上的排阻色譜以消除由於二聚體或其他多聚體存在而潛在的聚集體。在更優選的方式中,全部這些技術可以同時或者連續使用。
本文使用的術語“海兔毒素肽(dolastatin)”是指分離自一種海洋生物截尾海兔(Dollabella auricularia)的多肽,其包括但不限於海兔毒素肽10(dolastatin 10)和海兔毒素肽15(dolastatin 15)。海兔毒素肽是有絲分裂抑制劑,其表現出強的抗癌活性,因此被作為抗癌藥物的候選。研究人員進一步發現和合成了許多海兔毒素肽的衍生物,例如MMAE和MMAF。
本文使用的術語“連接子”是指抗體藥物綴合物(即ADC)中將抗體與藥物相連接的部分,其可以是可切割的或者不可切割的。可切割的連接子(即可斷裂的連接子或生物可降解連接子)可以在靶標細胞內或其上斷裂,從而釋放藥物。在某些實施方案中,本發明的連接子具有非常好的穩定性,大大減少了藥物在遞送到靶標過程中(例如在血液中)的釋放,從而減少了副作用和毒性。在一些特定實施方案中,本發 明的連接子選自可切割的連接子,例如基於二硫化物的連接子(其在巰基濃度更高的腫瘤細胞中選擇性斷裂)、肽連接子(其被腫瘤細胞中的酶所切割)、腙連接子。在另一些特定實施方案中,本發明的接頭選自不可切割的連接子(即,不可斷裂的連接子),例如硫醚連接子。在又一些實施方案中,本發明的連接子為可斷裂連接子與不可斷裂連接子的組合。優選地,本發明的連接子選自Mc-Val-Cit-PAB和Py-MAA-Val-Cit-PAB。
抗MSLN抗體
本發明的抗體藥物綴合物中的抗體的特徵在於特異性結合人MSLN。優選的是,該抗體以高親和力結合MSLN,例如,以1×10-7M或更小的KD。抗MSLN抗體優選顯示以下特性的一或多種:(a)以1×10-7M或更小的KD(例如,5×10-8M或更小、2×10-8M或更小、5×10-9M或更小、4×10-9M或更小、3×10-9M或更小、2×10-9M或更小)結合人MSLN;(b)結合MSLN高表達的Oval-Citar-3細胞,例如以2000ng/ml或更小的EC50(例如,1000ng/ml或更小、500ng/ml或更小、400ng/ml或更小、300ng/ml或更小、250ng/ml或更小、200ng/ml或更小、150ng/ml或更小、100ng/ml或更小、50ng/ml或更小、40ng/ml或更小、30ng/ml或更小、20ng/ml或更小、10ng/ml或更小、5ng/ml或更小),優選地所述EC50使用流式細胞術或酶標法進行測定;和(c)抑制表達MSLN細胞的體內生長。
單克隆抗體RC88
優選用於本發明的抗體藥物綴合物中的抗體為人單克隆抗體RC88。RC88的VH和VL氨基酸序列分別顯示在SEQIDNO:7和8。
在另一方面中,本發明的抗體可包括RC88的重鏈和輕鏈CDR1、CDR2和CDR3,或它們的組合。RC88的VHCDR1、VHCDR2、VHCDR3的氨基酸序列分別顯示在SEQ ID NO:1-3中。RC88的VLCDR1、VLCDR2、VLCDR3的氨基酸序列分別顯示在SEQ ID NO:4-6中。CDR區系用Kabat系統進行說明(Kabat,E.A.,etal..(1991).Sequences of Proteins of Immunological Interest,Fifth Edition,U.S.Department of Health and Human Services,NIH Publication NO:91-3242;以下稱之為“Kabat‘3242”)。
實施例
以下是本發明的方法和組合物的實施例。應當理解,鑒於上文提供的定義及一般描述,可以實施各種其他實施方案。
實施例1 抗間皮素抗體
使用標準方法產生免疫動物,從而產生本發明的抗間皮素抗體,例如可參見Kohler & Milstein,(1975)Nature 256:495-497,Kozbor et al.(1983)Immunol.Today 4:72以及Cole,et al.in MONOCLONAL ANTIBODIES AND CANCER THERAPY,Alan R.Liss,Inc.,1985,pp.77-96。
使用已知技術從細胞中分離並純化間皮素,並將其作為免疫原來免疫動物,例如可參見Zola,MONOCLONAL ANTIBODIES:PREPARATION AND USE OF MONOCLONAL ANTIBODIES AND ENGINEERED ANTIBODY DERIVATIVES(BASICS:FROM BACKGROUND TO BENCH)Springer-Verlag Ltd.,New York,2000;BASIC METHODS IN ANTIBODY PRODUCTION AND CHARACTERIZATION,Chapter 11,"Antibody Purification Methods," Howard and Bethell,Eds.,CRC Press,2000;ANTIBODY ENGINEERING(SPRINGER LAB MANUAL.),Kontermann and Dubel,Eds.,Springer-Verlag,2001。
從免疫動物中取出脾細胞,將其與骨髓瘤細胞系融合,得到雜交瘤。然後,通過篩選獲得高結合親和力的抗MSLN抗體。
通過移植輕鏈或重鏈CDR到人的IgG1或重鏈框架區來人源化鼠抗MSLN單克隆抗體。鼠源抗MSLN抗體輕鏈和重鏈的CDR用Kabat系統確定。通過對抗體可變區資料庫比對,我們確定了與鼠源MSLN抗體具有很高同源性的人IgG1框架區。由此,我們設計了不同的人源化MSLN抗體的輕鏈可變區序列和不同的人源化抗MSLN的重鏈可變區序列。根據這樣的設計,我們合成了人源化重鏈和輕鏈可變區序列,將人源化MSLN抗體輕鏈可變區與人kappa恒定區通過PCR融合,得到 人源化MSLN輕鏈全長;將人源化MSLN重鏈可變區與IgG恒定區用PCR方法融合,得到人源化MSLN重鏈全長。不同輕重鏈組合並表達,純化後的人源化抗體與人-鼠嵌合抗體進行ELISA結合親和力比較,篩選得到候選人源化抗體(命名為RC88抗體)。
下面表3示出了RC88抗體輕鏈和重鏈的CDR氨基酸序列。
RC88抗體的輕鏈和重鏈氨基酸序列分別如序列9(SEQ ID NO:9)和序列10(SEQ ID NO:10)所示。
實施例2 抗體藥物綴合物(ADC)的製備
實施例2a. 連接子-藥物綴合物的製備
①化合物1(Py-MAA-Val-Cit-PAB-OH)的合成
將化合物Py-MAA(1,3,5-三丙烯醯基六氫-1,3,5-三嗪-巰基乙酸,10.00g,29.3mmol)溶於DMF(200mL)中,加入HATU(16.73g,44.0mmol),Val-Cit-PAB-OH(9.20g,23.4mmol),DIPEA(15.32mL,87.9mmol),室溫攪拌24小時,TLC監測反應進程。反應完後,減壓旋蒸除去溶劑,粗品用製備型高效液相進行純化,製備液減壓旋蒸後得到化合物1(6.67g,32.4%,白色固體粉末)。
②化合物2(Py-MAA-Val-Cit-PAB-PNP)的合成
化合物1(7.02g,10.0mmol)溶於DMF(200mL)中,加入NPC(二(對硝基苯)碳酸酯),4.56g,15.0mmol)和DIPEA(2.09mL,12mmol),室溫反應5小時,TLC檢測反應進程。反應完成後,將反應液倒入石油醚(1500mL)中,攪拌,過濾,所得濾餅用石油醚洗滌(150mL×3),抽幹,得到類白色固體粉末(6.57g,75.7%)。
③化合物3(Py-MAA-Val-Cit-PAB-MMAE)的合成
化合物2(1.74g,2.2mmol)溶於20mL DMF中,氮氣保護下加入MMAE(1.44g,2.0mmol),HOBt(0.27g,2.0mmol),DIPEA(0.70mL,4.0mmol)和吡啶(4mL)。室溫攪拌24小時,TLC監測反應進程。反應結束後,用製備型高效色譜進行純化,製備液減壓旋蒸後得到化合物3(白色固體粉末,1.35g,46.7%)。LC-MS m/z(ES+),1446.35(M+H)+,IR(3334.32cm-1,2965.9cm-1,1652.70cm-1,1538.92cm-1,1436.71 cm-1)。
④化合物4(Py-MAA-Val-Cit-PAB-MMAD)的合成
化合物2(0.87g,1.1mmol)溶於10mL DMF中,氮氣保護下加入MMAD(0.77g,1.0mmol),HOBt(0.14g,1.0mmol),DIPEA(0.35mL,2.0mmol)和吡啶(2mL)。室溫攪拌24小時,TLC監測反應進程。反應結束後,用製備型高效色譜進行純化,製備液減壓旋蒸後得到化合物4(白色固體粉末,0.65g,43.5%)。LC-MS m/z(ES+),1499.76(M+H)+。
⑤化合物6(Mc-Val-Cit-PAB-PNP)的合成
化合物5(Mc-Val-Cit-PAB,4.58g,8.0mmol)溶於DMF(100mL)中,加入NPC(二(對硝基苯)碳酸酯),3.65g,12.0mmol)和DIPEA(1.70mL,9.6mmol),室溫反應5小時,TLC檢測反應進程。反應完成後,將反應液倒入石油醚(1000mL)中,攪拌,過濾,所得濾餅用石油醚洗滌(60mL×3),抽幹,得到類白色固體粉末(5.04g,85.2%)。
⑥化合物7(Mc-Val-Cit-PAB-MMAE)的合成
化合物6(1.19g,1.6mmol)溶於12mL DMF中,氮氣保護下加入MMAE(1.08g,1.5mmol),HOBt(0.21g,1.5mmol),DIPEA(0.55mL,3.0mmol)和吡啶(2.5mL)。室溫攪拌24小時,TLC監測反應進程。反應結束後,用製備型高效色譜進行純化,製備液減壓旋蒸後得到化合物7(白色固體粉末,0.891g,45.1%)。LC-MS m/z(ES+),1316.18(M+H)+。
⑦化合物8(Mc-Val-Cit-PAB-MMAD)的合成
化合物6(0.74g,1.1mmol)溶於10mL DMF中,氮氣保護下加入MMAD(0.77g,1.0mmol),HOBt(0.14g,1.0mmol),DIPEA(0.35mL,2.0mmol)和吡啶(2mL)。室溫攪拌24小時,TLC監測反應進程。反應結束後,用製備型高效色譜進行純化,製備液減壓旋蒸後得到化合物8(白色固體粉末,0.59g,42.8%)。LC-MS m/z(ES+),1369.38(M+H)+。
實施例2b. 抗體藥物綴合物的製備
將10mg/mL的RC88抗體、10mmol/L的DTPA(Diethylene triamine pentacetate acid,二乙基三胺五乙酸)以及5摩爾倍數的5mmol/L的TCEP(Tris-2-carboxyethyl-phosphine,三(2-羧乙基)膦)加入PCR管中,25℃攪拌反應2h,再於0℃下加入25%的DMSO(dimethyl sulfoxide,二甲亞碸)以及5摩爾倍數的5mmol/L的藥物(化合物3、4、7或8),25℃攪拌反應10h。反應結束後,用PBS緩衝液離心超濾3次,純化去除殘餘未反應藥物以及DMSO等游離小分子,並且利用SDS-PAGE電泳和疏水高效液相色譜(HIC-HPLC)法檢測偶聯情況。對RC88-PY-MAA-Val-Cit-PAB-MMAE和RC88-Mc-Val-Cit-PAB-MMAE用還原SDS-PAGE進行表徵,此次實驗採用Novex公司的NuPAGE預製膠,每個樣品總上樣體積為10μL,其結果如圖1所示。RC88-PY-MAA-Val-Cit-PAB-MMAE由於橋接連接子將還原後的二硫鍵又用共價鍵連接起來,因此存在不同情形的條帶,其中150kDa為完整抗體(LHHL),125kDa表示有一個輕鏈沒有被偶聯起來(LHH),100kDa為偶聯了兩個重鏈(HH),75kDa為偶聯了一個輕鏈一個重鏈(LH),50kDa和25kDa分別為重鏈和輕鏈。由於RC88-Mc-Val-Cit-PAB-MMAE不是橋接的連接子,二硫鍵還原成兩個巰基後分別與兩個連接子-毒素偶聯,因此還原SDS-PAGE僅顯示50kDa和25kDa兩個條帶。用疏水高效液相色譜(HIC-HPLC)法對RC88-PY-MAA-Val-Cit-PAB-MMAE和RC88-Mc-Val-Cit-PAB-MMAE的偶聯情況進行了檢測,結果分別如圖2A和圖2B所示,結果顯示DAR值分別為3.95(RC88-PY-MAA-Val-Cit-PAB-MMAE)和3.9(RC88-Mc-Val-Cit-PAB-MMAE)。
實施例3 高表達MSLN的Oval-Citar-3細胞的構建:
將生長狀態良好的Oval-Citar-3細胞(ATCC)以3x105/個孔接種至6孔板,貼壁過夜後,棄掉原培養基,加入含10μg/mL Polybrene(sigma)的新鮮培養基400μL,同時加入合適濃度的含有人MSLN編碼序列的慢病毒載體(pRRL-cmv)600μL,混勻後繼續培養24hr。培養結束後,更換新鮮培養基繼續擴大培養,使用流式細胞儀選擇陽性細胞。將所選的陽性細胞擴大培養,經流式細胞儀對MSLN表達量的分析後,選取MSLN表達量最高的細胞用於後續實驗(下文稱其為Oval-Citar-3-MSLN)。
實施例4 RC88抗體及RC88抗體藥物綴合物及相應連接子- 藥物、藥物的細胞毒活性檢測:
取生長狀態良好的Oval-Citar-3-MSLN細胞加入96孔細胞培養板(5×104個/mL,100μL/孔),CO2恒溫培養箱37℃孵育過夜。RC88抗體、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Py-MAA-Val-Cit-PAB-MMAD、RC88-Mc-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAD)及相應連接子-藥物(Py-Val-Cit-PAB-MMAE、Py-Val-Cit-PAB-MMAD、Mc-Val-Cit-PAB-MMAE、Mc-Val-Cit-PAB-MMAD)、藥物(MMAE、MMAD)、PTX(Paclitaxel,紫杉醇)用完全培養基分別稀釋,稀釋濃度分別為:RC88抗體、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Py-MAA-Val-Cit-PAB-MMAD、RC88-Mc-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAD)的終濃度為:0.32、1.6、8、16、32、64、128、640、3200ng/mL,連接子-藥物(Py-Val-Cit-PAB-MMAE、Py-Val-Cit-PAB-MMAD、Mc-Val-Cit-PAB-MMAE、Mc-Val-Cit-PAB-MMAD)的終濃度為:0.4、2、10、20、40、80、160、800、4000ng/mL,藥物(MMAE、MMAD)的終濃度為:0.0016、0.008、0.04、0.2、0.4、0.8、1.6、8、40ng/mL,PTX(Paclitaxel,紫杉醇)的終濃度:0.004、0.02、0.098、0.3、0.89、2.67、8、40、200ng/mL。 稀釋後加入96板(100μL/孔),設置空白組(未加藥的等量培養基)和三個對照組,CO2恒溫培養箱37℃孵育72h。加入含CCK-8 10μL的培養基(不含FBS)100μL/孔,CO2恒溫培養箱37℃孵育2-4hr,酶標儀讀取450nm處OD值,抑制率計算公式為:IR%=(OD空白-OD藥物)×100/OD空白。使用Prism軟體將抑制率作為y值,藥物濃度作為x值進行四參數曲線擬合,並記錄抑制率為介於最大抑制率和最小抑制率中間的值所對應的藥物濃度值(軟體預設為IC50值),結果見圖3和表4。結果顯示,RC88-Py-MAA-Val-Cit-PAB-MMAD、RC88-Mc-Val-Cit-PAB-MMAD、RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAE均能夠有效抑制Oval-Citar-3-MSLN)的生長。
實施例5 RC88抗體及RC88抗體藥物綴合物對MSLN高表達的Oval-Citar-3人卵巢癌荷瘤鼠模型的抑瘤實驗:
取生長狀態良好的Oval-Citar-3-MSLN細胞(2×106個),接種於裸鼠(常州卡文斯實驗動物有限公司,合格證編號:201611240,許可證號:SCXK(蘇)2011-0003)皮下,待腫瘤體積生長至約100-400mm3後將動物隨機分組。施用RC88抗體(2mg/kg)、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAD、RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAD,2mg/kg)及MMAE(0.0716mg/kg),每週給藥1次,共給藥3次,陰性對照組同時給等量的生理鹽水,結果見圖4、5和6。
結果顯示RC88抗體及RC88抗體藥物綴合物不影響荷瘤鼠體重增加;RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAD、 RC88-Py-MAA-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAE、RC88-Mc-Val-Cit-PAB-MMAD,2mg/kg)均表現出明顯的抑制荷瘤鼠移植瘤作用,而RC88抗體的抑瘤作用不明顯。
實施例6 RC88抗體藥物綴合物對MSLN高表達的Oval-Citar-3人卵巢癌荷瘤鼠模型的抑瘤實驗:
取正常生長的Oval-Citar-3-MSLN細胞(2×106個),接種於裸鼠(常州卡文斯實驗動物有限公司,合格證編號:201611240,許可證號:SCXK(蘇)2011-0003)皮下,待腫瘤體積生長至約100-400mm3後將動物隨機分組。實施所測試藥物RC88抗體(3mg/kg)、RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE 3mg/kg、1.5mg/kg、0.75mg/kg)MMAE 0.06mg/kg、RC88抗體(3mg/kg)+MMAE(0.06mg/kg)、人血清IgG-MMAE 3mg/kg、PTX(Paclitaxel,紫杉醇)10mg/kg,每週給藥1次,共給藥3次(PTX每週給藥2次,共給藥6次),陰性對照組同時給等量的生理鹽水,結果見圖7、8、9。試驗結果顯示RC88抗體藥物綴合物給藥劑量為3mg/kg組和1.5mg/kg組荷瘤鼠腫瘤在第一次給藥7天后明顯減小,3mg/kg組至給藥10天后無可見腫瘤,1.5mg/kg組至給藥17天后無可見腫瘤,0.75mg/kg組在給藥3次的情況下,腫瘤生長依然比較快,至給藥21天,腫瘤體積與對照(生理鹽水)組比較無統計學差異(P>0.05),且T/C>40%。紫杉醇(PTX)組至給藥21天,有兩隻荷瘤鼠的腫瘤完全消除(CR),腫瘤體積和RTV與對照(生理鹽水)組比較有統計學差異(P<0.05),且T/C<40%。紫杉醇(PTX)組與RC88抗體藥物綴合物給藥劑量3mg/kg組和1.5mg/kg組比較無統計學差異。RC88抗體、MMAE、RC88抗體+MMAE、IgG-MMAE與對照(生理鹽水)組比較無統計學差異(P>0.05)。
實施例7 RC88抗體及RC88抗體藥物綴合物與MSLN陽性腫瘤細胞的親和力檢測:
用流式細胞儀檢測RC88抗體及RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE)與MSLN陽性腫瘤細胞的親和力,取對數生長期Oval-Citar-3-MSLN細胞于1.5mL EP管中(每組4×105個),1500rpm離心5min,PBS充分洗滌一次,棄去上清液部分;用多聚甲醇(200μL 4%)重懸細胞,25℃固定15min,PBS充分洗滌一次,2500rpm離心3min,棄去上清液部分;用冷的1% BSA-PBS(牛 血清白蛋白-PBS)緩衝液將RC88抗體以及RC88抗體藥物綴合物從10000ng/mL 3倍梯度稀釋至1.52ng/mL,並分別取用各濃度溶液200μL重懸細胞,空白對照組直接用冷的1%BSA-PBS重懸,陰性對照組用1%BSA配製的濃度為5μg/mL的hIgG(中科晨宇)重懸細胞,4℃孵育30min,每10min顛倒混勻一次,使細胞孵育均勻;孵育結束,用冷的PBS洗一次,2500rpm,4℃離心3min,棄上清;每管加入冷的PBS 1:200稀釋的FITC(Fluorescein Isothiocyanate,異硫氰酸螢光素)標記的羊抗人IgG Fcγ(Jackson ImmunoResearch)200μL,4℃孵育30min,每10min顛倒混勻一次,使細胞孵育均勻。孵育結束,用冷的PBS洗一次,2500rpm,4℃離心5min,棄上清;400μLPBS重懸細胞,轉移到流式細胞儀(BD Calibur)進行檢測,其結果見圖10。結果表明,RC88抗體及RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE)均與MSLN陽性腫瘤細胞有強結合親和力,EC50值分別為153.5ng/mL和251.4ng/mL。
實施例8 RC88抗體及RC88抗體藥物綴合物與MSLN陽性腫瘤細胞的結合活性檢測:
用酶標法檢測RC88抗體及RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE)與MSLN陽性腫瘤細胞的結合活性,取對數生長期Oval-Citar-3-MSLN,加入96孔細胞培養板(4×105個/mL,100μL/孔),CO2恒溫培養箱37℃孵育過夜,棄去上清液部分,以0.05%PBST緩衝液洗板3次(250μL/孔);每孔加入4%多聚甲醛100μL,25℃固定30分鐘後,以0.05%PBST緩衝液洗板3次(250μL/孔);每孔加入250μL3%BAS-PBST(牛血清白蛋白-PBST)緩衝液,室溫封閉2小時後,以0.05%PBST緩衝液充洗板3次(250μL/孔);加樣:1)結合曲線:用1%BAS-PBST緩衝液將RC88抗體及RC88抗體藥物綴合物從3000ng/mL 3倍梯度稀釋至0.05ng/mL後加入96孔板(100μL/孔);2)競爭曲線:將重組人MSLN蛋白(義翹神州)用1%BAS-PBST從10000ng/mL稀釋至0.51ng/mL,RC88抗體及RC88抗體藥物綴合物稀釋為20ng/mL後,與MSLN蛋白稀釋液等體積混合後,以100μL/孔加入96孔板;25℃孵育1小時後,洗板3次;每孔加入1%BAS-PBST稀釋的HRP(Horseradish Peroxidase,辣根過氧化物酶)標記的羊抗人IgG Fc(Bethyl)(1:2000),25℃孵育1小時後,洗板3次;TMB顯色試劑盒(康為世紀)避光顯色5-10分鐘,2M硫酸終止,用酶標儀讀板,其結果見圖11。試驗結果表明RC88抗體及 RC88抗體藥物綴合物均與MSLN陽性腫瘤細胞有較強結合,RC88抗體藥物綴合物較RC88抗體略有下降,但並沒有顯著性差異,EC50值分別為11.0±0.81ng/mL和19.7±5.80ng/mL。通過與重組人MSLN蛋白的競爭實驗可證明RC88抗體及RC88抗體藥物綴合物與Oval-Citar-3-MSLN細胞表面的MSLN結合具有特異性。
實施例9 RC88抗體及RC88抗體藥物綴合物、CA125與MSLN的競爭性結合:
利用ELISA法檢測RC88抗體及RC88抗體藥物綴合物(RC88-Py-MAA-Val-Cit-PAB-MMAE)、CA125與MSLN的競爭性結合能力。用重組蛋白MSLN(義翹神州,200ng/mL)包被ELISA板。加樣:將RC88抗體及RC88抗體藥物綴合物用1%BAS-PBST(牛血清白蛋白-PBST)緩衝液從20μg/mL起梯度稀釋10個點(50μL/孔),將重組蛋白CA125(his tag,R&D)用1%BAS-PBST緩衝液稀釋至200ng/mL(50μL/孔),反應總體系100μL/孔,稀釋二抗(小鼠抗his單抗,R&D)5000倍,100μL/孔,TMB(3,3',5,5'-Tetramethylbenzidine,3,3',5,5'-四甲基聯苯胺)顯色5-7min,之後2M硫酸終止反應,用酶標儀450nm處讀板,其結果見圖12。結果顯示,隨著RC88抗體及RC88抗體藥物綴合物濃度的升高,重組CA125蛋白與重組人MSLN蛋白的結合降低,表明RC88抗體及RC88抗體藥物綴合物可以阻斷重組人CA125蛋白與重組人MSLN蛋白的結合。
以上描述地僅是優選實施方案,其只作為示例而不限制實施本發明所必需特徵的組合。所提供的標題並不意指限制本發明的多種實施方案。術語例如“包含”、“含”和“包括”不意在限制。此外,除非另有說明,沒有數詞修飾時包括複數形式,以及“或”、“或者”意指“和/或”。除非本文另有定義,本文使用的所有技術和科學術語的意思與本領域 技術人員通常理解的相同。
本申請中提及的所有公開物和專利通過引用方式併入本文。不脫離本發明的範圍和精神,本發明的所描述的方法和組合物的多種修飾和變體對於本領域技術人員是顯而易見的。雖然通過具體的優選實施方式描述了本發明,但是應該理解所要求保護的本發明不應該被不適當地局限於這些具體實施方式。事實上,那些對於相關領域技術人員而言顯而易見的用於實施本發明的所描述的模式的多種變體意在包括在隨附的請求項的範圍內。
<110> 榮昌生物製藥(煙臺)有限公司
<120> 一種抗間皮素抗體及其抗體藥物綴合物
<140> 108117459
<141> 2019-05-21
<150> CN 201810487856.4
<151> 2018-05-21
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 10
<212> PRT
<213> Artificial sequence
<210> 2
<211> 17
<212> PRT
<213> Artificial sequence
<210> 3
<211> 14
<212> PRT
<213> Artificial sequence
<210> 4
<211> 10
<212> PRT
<213> Artificial sequence
<210> 5
<211> 7
<212> PRT
<213> Artificial sequence
<210> 6
<211> 9
<212> PRT
<213> Artificial sequence
<210> 7
<211> 124
<212> PRT
<213> Artificial sequence
<210> 8
<211> 106
<212> PRT
<213> Artificial sequence
<210> 9
<211> 233
<212> PRT
<213> Artificial sequence
<210> 10
<211> 473
<212> PRT
<213> Artificial sequence
Claims (17)
- 一種抗體藥物綴合物,其具有式Ab-(L-D)n,其中:(a)Ab為特異性結合MSLN的抗體或其功能性片段,所述抗體或其功能性片段包含重鏈和輕鏈,其中(i)所述重鏈包含重鏈CDR1、CDR2和CDR3,所述重鏈CDR1、CDR2和CDR3具有如SEQ ID NO:1、2或3所示的氨基酸序列,並且(ii)所述輕鏈包含輕鏈CDR1、CDR2和CDR3,所述輕鏈CDR1、CDR2和CDR3具有如SEQ ID NO:4、5或6所示的氨基酸序列;(b)L為連接子或不存在;(c)D為治療劑;並且(d)n為1、2、3、4、5、6、7或8。
- 根據請求項1所述的抗體藥物綴合物,其中所述特異性結合MSLN的抗體包含重鏈可變區和輕鏈可變區,其中(i)所述重鏈可變區包含SEQ ID NO:7所示的氨基酸序列;並且(ii)所述輕鏈可變區包含SEQ ID NO:8所示的氨基酸序列。
- 根據請求項1或2中所述的抗體藥物綴合物,其中所述抗體是單克隆抗體、嵌合抗體、人源化抗體、單鏈抗體(scFv)或者雙特異性抗體。
- 根據請求項1或2所述的抗體藥物綴合物,其中所述治療劑為海兔毒素肽。
- 根據權利要求4所述的抗體藥物綴合物,其中所述治療劑為MMAD、MMAE或MMAF。
- 根據權利要求5所述的抗體藥物綴合物,其中所述治療劑為MMAE。
- 根據請求項1或2所述的抗體藥物綴合物,其中所述連接子與抗體通過抗體上的巰基連接。
- 一種能夠特異性結合間皮素的抗體或其功能性片段,其中所述抗體包含重鏈和輕鏈,其中(i)所述重鏈包含重鏈CDR1、CDR2和CDR3,所述重鏈CDR1、CDR2和CDR3具有如SEQ ID NO:1、2或3所示的氨基酸序列;(ii)所述輕鏈包含輕鏈CDR1、CDR2和CDR3,所述輕鏈CDR1、CDR2和CDR具有如SEQ ID NO:4、5或6所示的氨基酸序列。
- 根據請求項10所述的抗體或其功能性片段,其中所述抗體包含重鏈可變區和輕鏈可變區,(i)所述重鏈可變區包含SEQ ID NO:7所示的氨基酸序列;(ii)所述輕鏈可變區包含SEQ ID NO:8所示的氨基酸序列。
- 根據請求項10或11所述的任一抗體或其功能性片段,其中所述抗體是單克隆抗體、嵌合抗體、人源化抗體、單鏈抗體(scFv)或者雙特異性抗體。
- 一種分離的多核苷酸,其編碼根據請求項10所述的抗體或其功能性片段。
- 一種分離的多核苷酸的組合,其包括:編碼請求項10所述抗體或其功能性片段之重鏈的多核苷酸和編碼請求項10所述抗體或其功能性片段之輕鏈的多核苷酸。
- 一種表達載體或者表達載體的組合,其包含根據請求項13的多核苷酸或者根據請求項14的多核苷酸的組合,所述多核苷酸與允許其所編碼的多肽在宿主細胞或無細胞表達系統中表達的調節序列有效連接。
- 一種藥物組合物,其包含請求項1的抗體藥物綴合物和/或請求項 10的抗體或其功能性片段,以及可藥用載體。
- 一種請求項1的抗體藥物綴合物、請求項10的抗體或其功能性片段或請求項16的藥物組合物在製備用於治療或預防間皮素陽性癌症的藥物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810487856.4A CN110507824A (zh) | 2018-05-21 | 2018-05-21 | 一种抗间皮素抗体及其抗体药物缀合物 |
CN201810487856.4 | 2018-05-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202003040A TW202003040A (zh) | 2020-01-16 |
TWI714092B true TWI714092B (zh) | 2020-12-21 |
Family
ID=68616215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108117459A TWI714092B (zh) | 2018-05-21 | 2019-05-21 | 一種抗間皮素抗體及其抗體藥物綴合物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20220056147A1 (zh) |
EP (2) | EP3695852A4 (zh) |
JP (3) | JP2021523874A (zh) |
KR (3) | KR20200120728A (zh) |
CN (3) | CN110507824A (zh) |
AU (2) | AU2019272250B2 (zh) |
BR (2) | BR112020014380A2 (zh) |
CA (2) | CA3082160C (zh) |
RU (2) | RU2747995C1 (zh) |
SG (2) | SG11202011159QA (zh) |
TW (1) | TWI714092B (zh) |
WO (2) | WO2019223579A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11717575B2 (en) | 2019-05-20 | 2023-08-08 | Mabplex International Co., Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
AU2021282669A1 (en) | 2020-06-05 | 2023-01-05 | Development Center For Biotechnology | Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof |
CN111560072B (zh) | 2020-07-16 | 2020-12-11 | 上海恒润达生生物科技有限公司 | 抗人msln抗体以及靶向msln的免疫效应细胞 |
EP4129335A4 (en) * | 2020-09-01 | 2024-04-24 | RemeGen Co., Ltd. | ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS |
JP2023169444A (ja) * | 2020-10-01 | 2023-11-30 | 株式会社Epsilon Molecular Engineering | 標的タンパク質と結合し得る架橋ペプチド、当該架橋ペプチドの作製方法、及び当該架橋ペプチドを有効成分とする医薬組成物 |
EP4313164A1 (en) * | 2021-03-31 | 2024-02-07 | RemeGen Co., Ltd. | Preparation and purification method for antibody drug conjugate intermediate |
WO2022237666A1 (zh) | 2021-05-08 | 2022-11-17 | 荣昌生物制药(烟台)股份有限公司 | 一种抗Claudin18.2抗体及其抗体药物偶联物 |
WO2022262859A1 (zh) * | 2021-06-18 | 2022-12-22 | 江苏先声药业有限公司 | 抗人msln人源化抗体及其应用 |
CN116410332A (zh) * | 2021-12-29 | 2023-07-11 | 上海细胞治疗集团有限公司 | 抗间皮素纳米抗体嵌合抗原受体及其应用 |
KR20230125129A (ko) * | 2022-02-17 | 2023-08-29 | 주식회사 노벨티노빌리티 | 항체-약물 접합체 |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
CN117624284A (zh) * | 2023-11-29 | 2024-03-01 | 成都普康唯新生物科技有限公司 | 连接子的液相合成方法及其合成产物 |
CN117843793B (zh) * | 2024-03-07 | 2024-07-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201529084A (zh) * | 2009-04-29 | 2015-08-01 | Bayer Ip Gmbh | 抗-間皮素的免疫接合物及其用途 |
TWI589589B (zh) * | 2010-12-20 | 2017-07-01 | 建南德克公司 | 抗間皮素(mesothelin)抗體及免疫接合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1507556T3 (en) * | 2002-05-02 | 2016-09-12 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
KR101520209B1 (ko) * | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
BRPI0510883B8 (pt) * | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
EP2446904B1 (en) * | 2006-05-30 | 2015-04-29 | Genentech, Inc. | Anti-CD22 antibodies, their immunoconjugates and uses thereof |
JP5925875B2 (ja) * | 2011-04-01 | 2016-05-25 | ワイス・エルエルシー | 抗体−薬剤コンジュゲート |
CA2867824A1 (en) * | 2012-05-01 | 2013-11-07 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
CN106279352B (zh) * | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
PL3334462T3 (pl) * | 2015-08-14 | 2022-05-09 | RemeGen Biosciences, Inc. | Kowalencyjne linkery w koniugatach przeciwciało-lek oraz sposoby ich wytwarzania i zastosowania |
WO2017172907A1 (en) * | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
RU2018139811A (ru) * | 2016-04-15 | 2020-05-15 | Займворкс Инк. | Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства |
JP6727052B2 (ja) * | 2016-07-19 | 2020-07-22 | 株式会社日立製作所 | 生体分子分析用デバイス及び生体分子分析装置 |
CN106938051B (zh) * | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
AU2018358883A1 (en) * | 2017-10-30 | 2020-04-23 | F. Hoffmann-La Roche Ag | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
-
2018
- 2018-05-21 CN CN201810487856.4A patent/CN110507824A/zh not_active Withdrawn
-
2019
- 2019-05-15 EP EP19808424.6A patent/EP3695852A4/en active Pending
- 2019-05-15 AU AU2019272250A patent/AU2019272250B2/en active Active
- 2019-05-15 JP JP2020535025A patent/JP2021523874A/ja active Pending
- 2019-05-15 RU RU2020113275A patent/RU2747995C1/ru active
- 2019-05-15 BR BR112020014380-4A patent/BR112020014380A2/pt unknown
- 2019-05-15 US US16/644,842 patent/US20220056147A1/en active Pending
- 2019-05-15 SG SG11202011159QA patent/SG11202011159QA/en unknown
- 2019-05-15 CA CA3082160A patent/CA3082160C/en active Active
- 2019-05-15 KR KR1020207026535A patent/KR20200120728A/ko not_active IP Right Cessation
- 2019-05-15 CN CN201980002416.8A patent/CN110740754B/zh active Active
- 2019-05-15 KR KR1020237030872A patent/KR20230135164A/ko not_active Application Discontinuation
- 2019-05-15 WO PCT/CN2019/086977 patent/WO2019223579A1/zh unknown
- 2019-05-20 RU RU2019142484A patent/RU2724436C1/ru active
- 2019-05-20 US US16/618,110 patent/US20200138968A1/en active Pending
- 2019-05-20 SG SG11202006515VA patent/SG11202006515VA/en unknown
- 2019-05-20 JP JP2020515844A patent/JP6949206B2/ja active Active
- 2019-05-20 EP EP19807031.0A patent/EP3797795A4/en active Pending
- 2019-05-20 BR BR112020005596-4A patent/BR112020005596A2/pt active Search and Examination
- 2019-05-20 CN CN201980002405.XA patent/CN110740753A/zh active Pending
- 2019-05-20 KR KR1020207020184A patent/KR102454638B1/ko active IP Right Grant
- 2019-05-20 AU AU2019268215A patent/AU2019268215B2/en active Active
- 2019-05-20 WO PCT/CN2019/087641 patent/WO2019223653A1/zh unknown
- 2019-05-20 CA CA3062265A patent/CA3062265C/en active Active
- 2019-05-21 TW TW108117459A patent/TWI714092B/zh active
-
2023
- 2023-06-20 JP JP2023100937A patent/JP2023134472A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201529084A (zh) * | 2009-04-29 | 2015-08-01 | Bayer Ip Gmbh | 抗-間皮素的免疫接合物及其用途 |
TWI589589B (zh) * | 2010-12-20 | 2017-07-01 | 建南德克公司 | 抗間皮素(mesothelin)抗體及免疫接合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI714092B (zh) | 一種抗間皮素抗體及其抗體藥物綴合物 | |
JP6333882B2 (ja) | 抗体−薬剤コンジュゲート | |
JP6326137B2 (ja) | 抗her2抗体及びその結合体 | |
EA036882B1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
JP2022519273A (ja) | 抗cd228抗体及び抗体薬物コンジュゲート | |
JP2019500335A (ja) | 新規の抗クローディン抗体及び使用方法 | |
US20220356246A1 (en) | Anti-ROR1 antibodies and preparation method and uses thereof | |
CN106146664B (zh) | 针对肾相关抗原1的抗体及其抗原结合片段 | |
WO2022228406A1 (zh) | 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途 | |
JP2010508043A (ja) | 抗体産生を改善するための方法 | |
TWI767139B (zh) | 抗her2抗體藥物偶聯物在治療尿路上皮癌中的用途 | |
TW201731879A (zh) | 抗5t4抗體和抗體-藥物共軛體 | |
EP4215546A1 (en) | Anti-nectin-4 antibody, conjugate including same, and application thereof | |
WO2005047328A2 (en) | Antibodies against secretoryleukocyte protease inhibitor | |
EP3710485B1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
WO2023025243A1 (zh) | 抗Nectin-4抗体、药物缀合物及其制备方法和用途 | |
CN118159300A (zh) | 一种抗体及其药物偶联物和用途 | |
TWI846095B (zh) | 抗cd47-cldn18.2雙特異性抗體及其用途 | |
CN115594762A (zh) | 一种铁蛋白重链抗体及其用途 | |
JP2024525624A (ja) | 抗体薬物コンジュゲート及びその使用 | |
CN115197323A (zh) | 一种sn38抗体或其抗原结合片段及其应用 | |
CN118076633A (zh) | 人源化抗-人βig-h3蛋白及其用途 |